• In late May 2026, Merck reported that its investigational KRAS G12C inhibitor calderasib (MK-1084), when combined with KEYTRUDA, received FDA Breakthrough Therapy designation for first-line treatment of advanced or metastatic non-small cell lung cancer with KRAS G12C mutation and PD-L1 expression of at least 1%, backed by early positive Phase 1 KANDLELIT-001 data.
• This designation, alongside recent European support for KEYTRUDA-based combinations, underlines how Merck is using next-generation oncology partnerships and trial programs to broaden its cancer portfolio beyond current flagship therapies.
• We’ll now examine how this Breakthrough Therapy designation for calderasib plus KEYTRUDA could reshape Merck’s investment narrative and long-term oncology story.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Merck Investment Narrative Recap

To own Merck, you need to believe its broad late‑stage pipeline can offset future pressure on KEYTRUDA while supporting earnings growth and ongoing dividends. The calderasib plus KEYTRUDA Breakthrough Therapy designation is directionally positive for that narrative, but it does not change the near term focus on KEYTRUDA’s patent timeline as the key catalyst, or the looming loss of exclusivity as the central risk.

The most relevant nearby development is Europe’s positive CHMP opinion for KEYTRUDA plus Padcev in resectable muscle‑invasive bladder cancer, which, like calderasib, speaks to Merck’s push to extend KEYTRUDA‑based combinations into earlier treatment settings. Together, these oncology updates feed into the same core question for investors: how effectively can Merck convert this expanding cancer portfolio into durable post‑KEYTRUDA cash flows?

Yet investors should be aware that growing regulatory and pricing pressure in key markets could materially affect how much of this oncology progress ultimately reaches Merck’s bottom line...

Merck's narrative projects $76.5 billion revenue and $23.7 billion earnings by 2029. This requires 5.1% yearly revenue growth and a roughly $14.8 billion earnings increase from $8.9 billion today.

Uncover how Merck's forecasts yield a $129.74 fair value, a 8% upside to its current price.

Exploring Other Perspectives

More optimistic analysts already expected Merck to lift annual revenue to about US$80.1 billion and earnings to roughly US$30.8 billion, and the calderasib news could either reinforce that upbeat view or challenge it, depending on how you weigh the added oncology opportunity against the risk that tighter global pricing rules limit the payoff from these new cancer regimens.

Explore 9 other fair value estimates on Merck - why the stock might be worth as much as 90% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.